Payment overview · 2025
General Payments
$1,513.55
21 reported records · 4 companies
Healthcare provider profile · identity verified
Sami H Moussa, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WHITEHALL, PA · NPI 1386630424
Verified facts
What the public records show
CMS Open Payments records show Sami H Moussa, MD received $1,513.55 in general payments during 2025 across 21 reported records.
Phathom Pharmaceuticals, Inc. accounted for 81.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Voquezna, Xifaxan.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Ozempic by this doctor in 2024.
Phathom Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VOQUEZNA as an associated drug or biological on 90302 records involving 33442 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Voquezna by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trulance by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $1,231.83 | 81.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $218.28 | 14.4% | 14 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $35.04 | 2.3% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $28.40 | 1.9% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,120.00 | 1 |
| Food and Beverage | $393.55 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $1,231.83 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $218.28 | 14 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $218.28 | 14 | 2025 |
Source payment records
|
|||||
| Tresiba Normalized: tresiba |
Drug | Novo Nordisk Inc | $37.37 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $35.04 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $28.40 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 145 | exact normalized | Medicare Part D |
| VOQUEZNA voquezna |
2025 | Voquezna | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
145 | 35 |
| Phathom Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | VOQUEZNA open payments reported associated product |
CMS Open Payments — General Payments 90302 supporting records · 33442 recipient NPIs · example record 1219216983 |
Voquezna · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 921 | 218 |
| Amlodipine Besylate | Amlodipine Besylate | 850 | 197 |
| Atorvastatin Calcium | Atorvastatin Calcium | 817 | 187 |
| Metoprolol Succinate | Metoprolol Succinate | 598 | 145 |
| Levothyroxine Sodium | Levothyroxine Sodium | 550 | 113 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 497 | 125 |
| Gabapentin | Gabapentin | 477 | 103 |
| Diclofenac Sodium | Diclofenac Sodium | 431 | 103 |
| Metformin Hcl | Metformin Hcl | 386 | 93 |
| Lisinopril | Lisinopril | 354 | 85 |
| Tamsulosin Hcl | Tamsulosin Hcl | 309 | 74 |
| Metoprolol Tartrate | Metoprolol Tartrate | 305 | 69 |
| Glipizide | Glipizide | 276 | 63 |
| Valsartan | Valsartan | 272 | 64 |
| Prednisone | Prednisone | 269 | 127 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 251 | 47 |
| Eliquis | Apixaban | 238 | 50 |
| Losartan Potassium | Losartan Potassium | 224 | 54 |
| Torsemide | Torsemide | 208 | 40 |
| Famotidine | Famotidine | 204 | 61 |
| Clopidogrel | Clopidogrel Bisulfate | 179 | 37 |
| Alprazolam | Alprazolam | 174 | 35 |
| Furosemide | Furosemide | 172 | 44 |
| Linzess | Linaclotide | 161 | 35 |
| Spironolactone | Spironolactone | 159 | 34 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 158 | 47 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 149 | 36 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 149 | 24 |
| Ozempic | Semaglutide | 145 | 35 |
| Ipratropium Bromide | Ipratropium Bromide | 143 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 142 | 41 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 139 | 33 |
| Ezetimibe | Ezetimibe | 138 | 31 |
| Fenofibrate | Fenofibrate | 134 | 28 |
| Doxycycline Hyclate | Doxycycline Hyclate | 131 | 96 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 131 | 47 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 130 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 130 | 39 |
| Farxiga | Dapagliflozin Propanediol | 127 | 38 |
| Mirtazapine | Mirtazapine | 125 | 22 |
| Potassium Chloride | Potassium Chloride | 122 | 28 |
| Allopurinol | Allopurinol | 120 | 26 |
| Finasteride | Finasteride | 109 | 25 |
| Glipizide Er | Glipizide | 109 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 109 | 28 |
| Omeprazole | Omeprazole | 102 | 28 |
| Mupirocin | Mupirocin | 100 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 99 | 24 |
| Montelukast Sodium | Montelukast Sodium | 99 | 21 |
| Carvedilol | Carvedilol | 98 | 24 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 97 | 21 |
| Meclizine Hcl | Meclizine Hcl | 96 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 89 | 21 |
| Levofloxacin | Levofloxacin | 89 | 72 |
| Metformin Hcl Er | Metformin Hcl | 88 | 22 |
| Fenofibrate | Fenofibrate Nanocrystallized | 84 | 29 |
| Diflunisal | Diflunisal | 82 | 31 |
| Lorazepam | Lorazepam | 82 | 17 |
| Fluconazole | Fluconazole | 79 | 28 |
| Amitriptyline Hcl | Amitriptyline Hcl | 76 | 14 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 73 | 12 |
| Januvia | Sitagliptin Phosphate | 72 | 15 |
| Celecoxib | Celecoxib | 70 | 28 |
| Etodolac | Etodolac | 69 | 20 |
| Trulicity | Dulaglutide | 69 | 14 |
| Mounjaro | Tirzepatide | 67 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 65 | 12 |
| Sertraline Hcl | Sertraline Hcl | 63 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 62 | 46 |
| Tradjenta | Linagliptin | 62 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 60 | 50 |
| Ondansetron Odt | Ondansetron | 60 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 60 | 22 |
| Ofloxacin | Ofloxacin | 59 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 14 |
| Ketoconazole | Ketoconazole | 57 | 12 |
| Prolia | Denosumab | 57 | 38 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 56 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 54 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 52 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 51 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 51 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 49 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 48 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | suppressed |
| Xarelto | Rivaroxaban | 44 | suppressed |
| Amoxicillin | Amoxicillin | 42 | 39 |
| Jardiance | Empagliflozin | 42 | suppressed |
| Pregabalin | Pregabalin | 42 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 40 | suppressed |
| Atenolol | Atenolol | 39 | 11 |
| Digoxin | Digoxin | 38 | suppressed |
| Lidocaine | Lidocaine | 38 | suppressed |
| Haloperidol | Haloperidol | 36 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 35 | suppressed |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | suppressed |
| Meloxicam | Meloxicam | 35 | 13 |
| Metronidazole | Metronidazole | 35 | 30 |
| Silodosin | Silodosin | 35 | suppressed |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Ranolazine Er | Ranolazine | 31 | suppressed |
| Simvastatin | Simvastatin | 31 | suppressed |
| Trulance | Plecanatide | 31 | suppressed |
| Methocarbamol | Methocarbamol | 30 | 13 |
| Donepezil Hcl | Donepezil Hcl | 29 | 12 |
| Colchicine | Colchicine | 28 | 12 |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 28 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 28 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Levetiracetam Er | Levetiracetam | 26 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 25 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Scopolamine | Scopolamine | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Lumigan | Bimatoprost | 24 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Procto-Med Hc | Hydrocortisone | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Epinephrine | Epinephrine | 21 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 21 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 21 | 14 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | 15 |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | 16 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Comfort Touch Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 18 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Folic Acid | Folic Acid | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 15 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 15 | suppressed |
| Clobazam | Clobazam | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 15 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Voquezna | Vonoprazan Fumarate | 15 | suppressed |
| Dulera | Mometasone/Formoterol | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Neomycin-Bacitracin-Polymyxin | Neomycin/Bacitracin/Polymyxinb | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Ubrelvy | Ubrogepant | 14 | suppressed |
| Xifaxan | Rifaximin | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Dupixent Syringe | Dupilumab | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Ramelteon | Ramelteon | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Nizatidine | Nizatidine | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,513.55 · 21 records | Phathom Pharmaceuticals, Inc. | IBSRELA, Ozempic, Rybelsus, Tresiba, VOQUEZNA, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error